SEND Dataset Automation: Cutting Weeks Off Nonclinical Reporting
SEND (Standard for Exchange of Nonclinical Data) is the CDISC data format the FDA requires for most nonclinical safety study submissions, mandatory for NDAs since December 2016 and INDs since December 2017. SEND dataset automation means generating that submission-ready dataset directly from the study's operating record as data is collected, instead of reconstructing it...
Why Preclinical CROs Need More Than a LIMS
A LIMS captures study data. It doesn't run your CRO. See how SIMS gives preclinical CROs a connected operating layer for capacity and compliance.
GLP Audit-Readiness: Why Continuous Compliance Beats Last-Minute Prep
GLP audit-readiness means a nonclinical safety study's records, consistent with 21 CFR Part 58 and OECD GLP, could withstand inspection on any given day, not just after a pre-audit scramble. Most compliance software addresses this by logging what happened after the fact. SIMS addresses it by mapping every study activity to its governing SOP...
PointCross Launches Xbiom SIMS, a Digital Transformation Platform for Preclinical Study Operations
Discover Xbiom SIMS by PointCross, a digital platform transforming preclinical study operations through integrated workflows, real-time monitoring, automated study reporting and SEND generation.
PointCross Presents on Metadata-Driven Data for Deterministic AI at PHUSE Shanghai 2026
PointCross Life Sciences participated in the PHUSE Shanghai Single Day Event 2026, where Pingping Gong represented PointCross with a presentation titled "Beyond SDTM/SEND: Metadata-Driven Data for Deterministic AI."
PointCross at ACT 2026: A Recap of SIMS, Automation, and Great Conversations
ACT 2026 has come to a close, and the PointCross Life Sciences team would like to thank everyone who stopped by Booth #613. It was a pleasure meeting so many professionals working across nonclinical safety, and we enjoyed every conversation about the evolving role of automation and data integration in nonclinical studies. SIMS in the...
Why Submission Dataset Validation Breaks
PointCross Life Sciences has standardized nonclinical study data for FDA and PMDA submissions since 2009, and in that time one pattern has repeated itself across sponsors of every size: the submission package clears the validator, the team exhales, and six weeks later an FDA reviewer flags the data as unusable. The validator was never...
What Causes SDTM, ADaM and SEND Validation Failures
SDTM, ADaM, and SEND datasets form the backbone of regulatory submissions to the FDA, PMDA, and other agencies. Yet validation failures in these datasets remain one of the most common obstacles to achieving submission readiness. Understanding why these failures occur helps clinical data managers and operations leaders address root causes rather than just fixing...
How to Fix SEND Compliance Gaps in Mid-Sized Biotechs
Learn how mid-sized biotechs can fix internal SEND compliance gaps. PointCross explains workflow issues, traceability solutions, and submission readiness steps.
PointCross Life Sciences Co-Hosted PHUSE Single Day Event in Foster City, CA
PointCross Life Sciences is proud to co-host the PHUSE Single Day Event (SDE) alongside Gilead Sciences on August 6, 2026, in Foster City, California. Centered around the theme, “Real-World Impact of Where AI Technology and Preclinical and Clinical Computation Meet,” the event will bring together industry leaders, researchers, and technology innovators to discuss how artificial...
SEND Validation for FDA and PMDA in 2026
Why SEND Validation Matters for Your FDA and PMDA Submissions Your nonclinical study data must clear FDA validation before a reviewer ever sees it. A malformed dataset, missing Trial Summary file, or mismatch between your SEND package and study report can trigger a refuse-to-file decision that delays your entire program by weeks or months. The Standard...
Produce a Study Report + SEND Dataset in 2–3 Weeks
Most nonclinical CROs take 8 to 10 weeks to deliver a study report and its SEND dataset, because two teams rebuild the same data twice. Here's how producing both from one governed source cuts that to 2 to 3 weeks after data lock, without loosening a single FDA requirement.
SEND Datasets: The Complete Guide
SEND datasets are the standardized, machine-readable files the U.S. FDA requires for nonclinical study data in most drug and biologics submissions. If you run toxicology studies, assemble regulatory filings, or manage data at a CRO, SEND datasets are no longer optional for in-scope studies. This guide explains what SEND is, who needs it, which...
SEND 4.0 Is Coming. Here’s What You Actually Need to Know.
CDISC opened public review for SENDIG v4.0 in April 2026, with publication targeted for Q4 2026. While the FDA has not yet announced an implementation timeline, many CROs and sponsors are watching from a distance. That posture has a cost. SENDIG v4.0 isn't just another version update. It introduces some of the most significant structural changes since its original release. The changes extend far beyond routine version...
Mitigating risk with PointCross
As some may have heard, the FDA released their bi-annual update to the Technical Conformance Guide earlier this year. Along with slight corrections and improvements, an entire Appendix was added regarding SEND data review "Best Practices". With the update, the FDA has formalized some industry wide best practices; better quality SEND datasets equates to...
5 SEND Compliance Challenges Nonclinical CROs Must Solve
This article breaks down the real SEND compliance challenges that nonclinical CROs face, grounded in current FDA and CDISC requirements, and shows where disciplined process and the right tooling change the outcome. We write this for toxicologists, regulatory affairs professionals, bioinformaticians, pharma and biotech executives, and the IT and data teams who live with...
The Business Case for Automating Nonclinical Study Reports
The study report and its SEND dataset are built twice from the same data. Automating nonclinical study reports deletes that duplication, cuts cost 30 to 50 percent, and removes the inconsistencies that trigger FDA queries.
FDA SEND Requirements for Nonclinical Studies: Which Studies Need SEND Datasets in 2026?
Complete FDA SEND guide: which nonclinical studies require SEND datasets, SENDIG 3.1.1, DART, AR, Genetox deadlines, GLP rules, and IND/NDA scope explained.
AI in Nonclinical Reporting: From Hype to Real Workflow
Discover how AI is transforming nonclinical study reporting, from automated Module 2.4 drafts to FDA-compliant eCTD outputs. What is working, what is not, and what the FDA's 2025 guidance requires.
SEND Dataset Quality: Why Passing the Validator Is Only Half the Battle
Learn why SEND datasets fail FDA review even after passing validators, what the 2026 TCG requires, and how PointCross guarantees submission-ready quality.